Sam Brusco, Associate Editor03.27.24
MTD (Medical Technology and Devices) has begun a deal to acquire Ypsomed’s pen needle and blood glucose monitoring (BGM) businesses.
MTD claims to be the second largest manufacturer of pen needles globally. The company said it will incorporate Ypsomed’s pen needle and BGMs portfolio to ensure long-term availability of an exclusively European manufactured, innovative pen needle offering.
Ypsomed is a developer and manufacturer of injection and infusion systems for self-medication. The company has been in operation for 40 years.
The transaction’s close is expected in summer 2024, after which the business transition will begin.
Charles Bouaziz, CEO of MTD, said: "This acquisition will enable us to accelerate growth and enter new strategic markets, leveraging a broader product portfolio combining the 6-bevels and click technologies from Ypsomed and MTD's thinnest and shortest 34G pen needle. We will integrate Ypsomed's pen needles operations and BGMs' commercialization into our European production and distribution sites, contributing to scale efficiencies and benefiting from our category expertise.”
"This acquisition enables MTD to open new, strategic markets, such as Germany, expand into high growth markets like China and India and strengthen our position in other important markets such as North America and France, reinforcing our commitment to supporting millions of diabetic patients, caregivers, and healthcare professionals worldwide," continued Bouaziz.
MTD claims to be the second largest manufacturer of pen needles globally. The company said it will incorporate Ypsomed’s pen needle and BGMs portfolio to ensure long-term availability of an exclusively European manufactured, innovative pen needle offering.
Ypsomed is a developer and manufacturer of injection and infusion systems for self-medication. The company has been in operation for 40 years.
The transaction’s close is expected in summer 2024, after which the business transition will begin.
Charles Bouaziz, CEO of MTD, said: "This acquisition will enable us to accelerate growth and enter new strategic markets, leveraging a broader product portfolio combining the 6-bevels and click technologies from Ypsomed and MTD's thinnest and shortest 34G pen needle. We will integrate Ypsomed's pen needles operations and BGMs' commercialization into our European production and distribution sites, contributing to scale efficiencies and benefiting from our category expertise.”
"This acquisition enables MTD to open new, strategic markets, such as Germany, expand into high growth markets like China and India and strengthen our position in other important markets such as North America and France, reinforcing our commitment to supporting millions of diabetic patients, caregivers, and healthcare professionals worldwide," continued Bouaziz.